Compare Stocks: ALVO, TVTX, KNSA, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.36 +0.3%	$3.86	$2.94 ▼ $9.25	$1.62B	0.21	682,157 shs	239,196 shs
KNSA Kiniksa Pharmaceuticals International	$79.81 -0.1%	$71.13	$35.06 ▼ $82.94	$6.22B	0.09	694,770 shs	163,201 shs
ORKA Oruka Therapeutics	$91.95 +0.3%	$95.11	$14.66 ▼ $115.51	$6.10B	-0.34	1.11 million shs	270,365 shs
TVTX Travere Therapeutics	$66.38 -1.3%	$59.95	$19.46 ▼ $68.03	$6.27B	1.05	2.03 million shs	385,824 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+1.91%	+8.76%	+40.90%	+42.78%	-32.83%
KNSA Kiniksa Pharmaceuticals International	+0.77%	+1.54%	+8.83%	+62.28%	+133.05%
ORKA Oruka Therapeutics	-0.52%	-7.85%	-3.33%	+47.13%	+488.88%
TVTX Travere Therapeutics	+2.31%	+0.16%	+22.28%	+45.58%	+270.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$5.36 +0.3%	$3.86	$2.94 ▼ $9.25	$1.62B	0.21	682,157 shs	239,196 shs
KNSA Kiniksa Pharmaceuticals International	$79.81 -0.1%	$71.13	$35.06 ▼ $82.94	$6.22B	0.09	694,770 shs	163,201 shs
ORKA Oruka Therapeutics	$91.95 +0.3%	$95.11	$14.66 ▼ $115.51	$6.10B	-0.34	1.11 million shs	270,365 shs
TVTX Travere Therapeutics	$66.38 -1.3%	$59.95	$19.46 ▼ $68.03	$6.27B	1.05	2.03 million shs	385,824 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+1.91%	+8.76%	+40.90%	+42.78%	-32.83%
KNSA Kiniksa Pharmaceuticals International	+0.77%	+1.54%	+8.83%	+62.28%	+133.05%
ORKA Oruka Therapeutics	-0.52%	-7.85%	-3.33%	+47.13%	+488.88%
TVTX Travere Therapeutics	+2.31%	+0.16%	+22.28%	+45.58%	+270.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.25	Hold	$7.50	40.06% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	9.47% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	44.65% Upside
TVTX Travere Therapeutics	2.69	Moderate Buy	$61.67	-7.10% Downside

Current Analyst Ratings Breakdown

Latest ALVO, TVTX, KNSA, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	ALVO Alvotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/17/2026	TVTX Travere Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/10/2026	TVTX Travere Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$78.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.95M	3.29	$0.22 per share	24.05	($0.63) per share	-8.50
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.19	$0.80 per share	99.88	$8.38 per share	9.52
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$16.79 per share	N/A
TVTX Travere Therapeutics	$490.73M	12.75	$0.37 per share	181.45	$0.26 per share	255.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	22.31	N/A	-36.31%	-11.92%	-11.73%	11/11/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	82.15	38.56	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
TVTX Travere Therapeutics	-$25.55M	-$0.46	N/A	25.24	N/A	-7.35%	-55.15%	-6.88%	10/29/2026 (Estimated)

Latest ALVO, TVTX, KNSA, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.22	$103.00 million	$106.00 million
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/4/2026	Q2 2026	TVTX Travere Therapeutics	-$0.1347	-$0.10	+$0.0347	-$0.37	$157.27 million	$169.58 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
ORKA Oruka Therapeutics	N/A	38.51	38.51
TVTX Travere Therapeutics	24.58	4.05	3.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
KNSA Kiniksa Pharmaceuticals International	53.95%
ORKA Oruka Therapeutics	56.44%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
KNSA Kiniksa Pharmaceuticals International	51.98%
ORKA Oruka Therapeutics	23.49%
TVTX Travere Therapeutics	4.44%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
ORKA Oruka Therapeutics	N/A	66.21 million	50.66 million	N/A
TVTX Travere Therapeutics	460	94.26 million	90.08 million	Optionable

ALVO, TVTX, KNSA, and ORKA Headlines

Recent News About These Companies

45,633 Shares in Travere Therapeutics, Inc. $TVTX Purchased by The Manufacturers Life Insurance Company

September 3 at 4:32 AM | marketbeat.com

Travere Therapeutics, Inc. $TVTX Stock Position Increased by Wellington Management Group LLP

September 2 at 5:03 AM | marketbeat.com

Corient Private Wealth LP Buys Shares of 48,073 Travere Therapeutics, Inc. $TVTX

September 2 at 3:51 AM | marketbeat.com

Empowered Funds LLC Buys New Stake in Travere Therapeutics, Inc. $TVTX

September 1 at 3:51 AM | marketbeat.com

Jefferies Financial Group Inc. Takes Position in Travere Therapeutics, Inc. $TVTX

August 30, 2026 | marketbeat.com

Legal & General Group Plc Makes New Investment in Travere Therapeutics, Inc. $TVTX

August 30, 2026 | marketbeat.com

220,611 Shares in Travere Therapeutics, Inc. $TVTX Bought by Hsbc Holdings PLC

August 29, 2026 | marketbeat.com

167,525 Shares in Travere Therapeutics, Inc. $TVTX Bought by Palo Alto Investors LP

August 28, 2026 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High - Time to Buy?

August 27, 2026 | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Still a Buy?

August 27, 2026 | marketbeat.com

Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX

August 27, 2026 | marketbeat.com

11,324,191 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Jupiter Topco LLC

August 26, 2026 | marketbeat.com

Elmind Capital LP Invests $16.62 Billion in Travere Therapeutics, Inc. $TVTX

August 26, 2026 | marketbeat.com

Deutsche Bank AG Purchases New Stake in Travere Therapeutics, Inc. $TVTX

August 23, 2026 | marketbeat.com

Travere Therapeutics Signals Strong Growth in Earnings Call

August 22, 2026 | theglobeandmail.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analysts

August 22, 2026 | marketbeat.com

IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'

August 21, 2026 | msn.com

Travere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High - Should You Buy?

August 21, 2026 | marketbeat.com

Lisanti Capital Growth LLC Makes New $6.76 Million Investment in Travere Therapeutics, Inc. $TVTX

August 20, 2026 | marketbeat.com

Travere Therapeutics: Valuation Suggests A Buy

August 19, 2026 | seekingalpha.com

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

August 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, TVTX, KNSA, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

$5.36 +0.02 (+0.28%)

As of 12:22 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$79.81 -0.08 (-0.10%)

As of 12:22 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Oruka Therapeutics NASDAQ:ORKA

$91.94 +0.32 (+0.34%)

As of 12:22 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Travere Therapeutics NASDAQ:TVTX

$66.38 -0.85 (-1.26%)

As of 12:23 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVO, TVTX, KNSA, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVO, TVTX, KNSA, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVO, TVTX, KNSA, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, TVTX, KNSA, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Oruka Therapeutics NASDAQ:ORKA

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVO, TVTX, KNSA, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVO, TVTX, KNSA, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVO, TVTX, KNSA, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, TVTX, KNSA, and ORKA Company Descriptions

Alvotech NASDAQ:ALVO

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Oruka Therapeutics NASDAQ:ORKA

Travere Therapeutics NASDAQ:TVTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools